首页 工具
登录
购物车
Stiripentol

Stiripentol

产品编号 T4498   CAS 49763-96-4
别名: 斯利潘托, BCX2600, Diacomit

Stiripentol (BCX2600) 是抗惊厥剂,对 CYP3A4 (非竞争性) 及 CYP2C19 (竞争性地) 介导的 CLB 向 N-desmethylclobazam (NCLB) 的 N-去甲基化具有抑制作用。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Stiripentol Chemical Structure
Stiripentol, CAS 49763-96-4
规格 价格/CNY 货期 数量
2 mg ¥ 256 现货
5 mg ¥ 413 现货
10 mg ¥ 648 现货
25 mg ¥ 1,320 现货
50 mg ¥ 1,830 现货
100 mg ¥ 2,970 现货
200 mg ¥ 4,360 现货
1 mL * 10 mM (in DMSO) ¥ 417 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
Doxorubicin hydrochloride限时半价
产品目录号及名称: Stiripentol (T4498)
点击图片重新获取验证码
选择批次  
纯度: 99.93%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Stiripentol (BCX2600) (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59/0.516 μM and IC50 of 1.58/3.29 μM, respectively.
靶点活性 CYP3A4:1.58 μM, CYP2C19:3.29 μM
体外活性 The inhibition of CLB demethylation by Stiripentol (STP) is best described by a noncompetitive inhibition model with apparent Ki (1.6 μM) for the cDNA-expressing CYP3A4 and by a competitive inhibition model with Ki (0.52 μM) for the cDNA-expressing CYP2C19. Formation of OH-NCLB from NCLB by cDNA-expressing CYP2C19 is competitively inhibited by Stiripentol (STP) with a Ki: 0.14 μM [1].
体内活性 In mice treating with Stiripentol (STP) monotherapy, the difference between BT1 (39.67±1.09°C) and BT2 (41.32±1.05°C) reaches statistical significance (t=3.097, p<0.05). The difference in BT2 between Stiripentol (STP) monotherapy and CLB monotherapy is statistically significant (t=2.615, p<0.05). In mice treating with Stiripentol (STP)+CLB combination therapy, the difference between BT1 (40.18±0.58°C) and BT2 (43.03±0.49°C) reaches statistical significance (t=10.44, p<0.01)[2].
细胞实验 The inhibition constants (apparent Ki) of Stiripentol (STP) for CLB demethylation by CYP3A4 and CYP2C19 are determined using various concentrations of CLB (2, 10, 20, 40, 60, and 100 μM) with increasing concentrations of Stiripentol (STP) (0, 0.5, 1, 2, and 5 μM). Concerning NCLB hydroxylation by CYP2C19, the apparent Ki is similarly determined with different concentrations of NCLB (1.5, 4, 6, 8, 12, and 14 μM) and STP (0, 0.1, 0.5, 1, and 2 μM). IC50 values are determined by coincubation of the substrate at the concentration in the range of the therapeutic plasma concentrations (2 μM CLB or 14 μM NCLB) with increasing concentrations of Stiripentol (STP) (0.001-10 μM) [1].
动物实验 Two age groups, p1M (n=18, age 4 weeks) and p5M (n=18, age 5-10 months), of Scn1aRX/+ mice are assigned in this experiment. Both groups are divided randomly into three subgroups (n=6), and each subgroup is administered Stiripentol (STP) (300 mg/kg) alone, CLB (6.62 mg/kg) alone, or a combination of Stiripentol (STP) (p1M; 150 mg/kg, p5M; 300 mg/kg) and CLB (6.62 mg/kg). All drugs are administered by intraperitoneal injection (i.p.) after a 48-h recovery from baseline seizure study. Blood samples are collected at 1 h and 20 min after administration of CLB or STP+CLB for measurement of plasma concentrations of CLB and N-desmethylclobazam, respectively [2].
别名 斯利潘托, BCX2600, Diacomit
分子量 234.29
分子式 C14H18O3
CAS No. 49763-96-4

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: 5 mg/mL

DMSO: 55 mg/mL (234.75 mM)

Ethanol: 30 mg/mL

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.2682 mL 21.3411 mL 42.6821 mL 106.7054 mL
5 mM 0.8536 mL 4.2682 mL 8.5364 mL 21.3411 mL
10 mM 0.4268 mL 2.1341 mL 4.2682 mL 10.6705 mL
20 mM 0.2134 mL 1.0671 mL 2.1341 mL 5.3353 mL
50 mM 0.0854 mL 0.4268 mL 0.8536 mL 2.1341 mL
100 mM 0.0427 mL 0.2134 mL 0.4268 mL 1.0671 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Giraud C, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.Drug Metab Dispos. 2006 Apr;34(4):608-11. Epub 2006 Jan 13. 2. Cao D, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome. Epilepsia. 2012 Jul;53(7):1140-5.

TargetMol Library Books文献引用

1. Avdeef A, Kansy M. Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE (Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression. Journal of Solution Chemistry. 2022: 1-36.
AG 045572 Clopidogrel hydrogen sulfate Pregnenolone Carbonitrile Topiroxostat Bergapten CAY10434 Ginsenoside C-K BMS-819881

相关化合物库

该产品包含在如下化合物库中:
抗癌临床化合物库 EMA 上市药物库 抗癌药物库 抗癌上市药物库 药物功能重定位化合物库 抑制剂库 已知活性化合物库 NO PAINS 化合物库 经典已知活性库 甲基化化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Stiripentol 49763-96-4 Metabolism P450 斯利潘托 Inhibitor BCX2600 inhibit BCX 2600 CYPs Diacomit BCX-2600 Cytochrome P450 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼